查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1726180

臨床實驗室匹配軟體市場規模、佔有率、趨勢分析報告（按部署模式、最終用途、地區、細分市場預測，2025 年至 2030 年）

Clinical Trials Matching Software Market Size, Share & Trends Analysis Report By Deployment Mode, By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

臨床測試匹配軟體市場的成長和趨勢

根據Grand View Research, Inc.的最新報告，到2030年全球臨床實驗室匹配軟體市場規模預計將達到3.9613億美元。

預計從 2025 年到 2030 年，其複合年成長率將達到 13.45%。正在進行的臨床試驗數量的大幅增加預計將推動市場的發展。此外，臨床測試中臨床測試匹配軟體的採用率不斷提高以及醫療保健領域對虛擬測試和自動化的需求不斷成長也是推動市場成長的主要因素。配對軟體有助於以患者為中心的方法實現有效、快速的患者配對。

在臨床試驗中，患者招募和配對可能非常耗時，而且找到合適的配對可能很困難。篩檢和找到符合條件的受訪者候選人、完成臨床實驗試驗的所有要素、確保意識、獲得參與的知情同意等是招募患者時考慮的一些因素。根據資格要求招募個人至關重要，因此試驗匹配技術已被證明是有用的，尤其是在 COVID-19 情況下。

該軟體不僅能找到正確的匹配，還能幫助節省研發相關成本，並確保無需任何人工干預即可順利運作。軟體供應商正在引入新的創新技術來鞏固其在市場上的地位。例如，2022 年 2 月，CTMA 擴展了其在風濕病學領域的 CT-SCOUT 技術產品。

臨床測試配對軟體市場報告重點

  • 按部署模式，預計 2024 年雲端基礎的細分市場將在收益方面佔據主導地位，並在預測期內實現最快的複合年成長率。雲端運算模式不需要維護或保養成本，客戶只需為他們使用的服務付費。另一方面，內部部署需要內部基礎架構、內部 IT 支援、營運資金和高昂的整合成本。這就是為什麼人們更喜歡雲端基礎的模型。
  • 根據最終用途，預計製藥和生物技術公司將在 2024 年佔據最大的收益佔有率。
  • 預計合約研究組織 (CRO) 部門在預測期內的複合年成長率最快。 CRO 可以快速提供臨床試驗所需的專業支援、專業知識和實施經驗，無需贊助商僱用專門人員。 CRO 服務具有成本效益和時間效益，使其成為受歡迎的外包目的地。
  • 由於北美地區的製藥、生物技術和醫療保健相關企業擴大採用臨床測試匹配軟體，預計到 2024 年北美將在公司收益方面領先市場。
  • 由於擁有大量患者群，支持輕鬆招募患者/候選人，預計亞太地區將在預測期內實現最快的成長率。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章臨床實驗室匹配軟體市場變數、趨勢和範圍

  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場機會分析
  • 臨床試驗配對軟體市場分析工具
    • 產業分析—波特五力分析
    • PESTEL分析
    • 新興技術
    • 使用案例和見解
    • COVID-19影響分析

第4章：臨床實驗室匹配軟體市場：部署模式、估計與趨勢分析

  • 部署模式市場佔有率（2024 年和 2030 年）
  • 細分儀表板
  • 全球臨床試驗配對軟體市場（按部署模式）展望
  • 雲端基礎
  • 本地

第5章臨床實驗室匹配軟體市場：按最終用途的估計和趨勢分析

  • 2024 年及 2030 年最終用途市場佔有率
  • 細分儀表板
  • 臨床試驗配對軟體市場前景（依最終用途）
  • 製藥和生物技術公司
  • CRO
  • 醫療設備公司

第6章臨床實驗室匹配軟體市場：區域估計和趨勢分析、部署模式和最終用途

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 2018-2030年市場規模及預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 2024年主要企業的市場佔有率/地位分析
  • 公司簡介
    • IBM
    • Antidote Technologies, Inc.
    • RealTime Software Solutions, LLC
    • Optimapharm.
    • Advarra
    • BSI Business Systems Integration AG
    • Clario
    • HealthMatch
    • Microsoft
    • Deep6.ai
    • Inspirata, Inc.
    • Mendel Health Inc.
    • MatchTrial
    • Curewiki
    • Inteliquet（IQVIA）
    • Tempus Labs
Product Code: GVR-4-68039-921-8

Clinical Trials Matching Software Market Growth & Trends:

The global clinical trials matching software market size is expected to reach USD 396.13 million by 2030, based on a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 13.45% from 2025 to 2030. The significant increase in the number of ongoing clinical trials is likely to drive the market. In addition, the growing adoption of the clinical trial matching software catering to the clinical trials, along with the increased demand for virtual trials and automation in the healthcare sector are some of the key factors contributing to the market growth. The matching software help in effective and fast patient matching with patient-centric approaches.

In clinical trials, patient recruitment or matching can be time-consuming, and finding the right match can be a hurdle. Screening or locating prospective respondents who are qualified, considering all elements of the trials, verifying awareness, and getting informed consent to participate are the factors taken into consideration while recruiting patients. Enlisting the individuals in accordance with the qualifying requirements is crucial, hence the trial matching technology has been proved to be useful, especially in the COVID-19 scenario.

The software helps not only to find the right match but also saves the R&D-related costs, enabling smoother operations without human intervention. The software providers are introducing new innovative techniques to strengthen their market position. For instance, in February 2022, the CTMA expanded CT-SCOUT technology offering in rheumatology.

Clinical Trials Matching Software Market Report Highlights:

  • Based on deployment mode, the web and cloud based segment dominated the market in terms of revenue in 2024 and it is expected to register the fastest CAGR during the forecast period. The cloud computing models operate with no maintenance or upkeep charges and customers only have to pay for the services that are used. On the other hand, on-premises deployment involves in-house infrastructure, in-house IT support, working capital, and higher integration costs. Hence, web and cloud based models are preferred
  • Based on end use, pharmaceuticals and biotechnology companies captured the largest revenue share in 2024 owing to the higher adoption of software during ongoing clinical studies for cost-saving in the R&D activities
  • Contract Research Organizations (CRO) segment is expected to register the fastest CAGR over the forecast period. CROs provide the professional assistance, expertise, and execution experience required for clinical trials quickly, without the need for the sponsor to engage such people full-time. CROs are preferred for outsourcing as their services are cost and time-effective
  • In 2024, North America led the market in terms of revenue owing to the rising adoption of the clinical trial matching software by the pharma, biotech, and medical companies in the region
  • Asia Pacific is anticipated to register the fastest growth rate over the forecast period due to the availability of a large patient pool supporting easy recruitment of patients/candidates

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Deployment mode
    • 1.1.2. End Use
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline.
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database.
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Approach 1: Commodity flow approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Deployment mode outlook
    • 2.2.2. End use
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Clinical Trials Matching Software Market Variables, Trends & Scope

  • 3.1. Market Dynamics
    • 3.1.1. Market Driver Analysis
      • 3.1.1.1. Growing Complexity of Clinical Trials
      • 3.1.1.2. Increasing Demand for Precision Medicine & Personalized Trials
      • 3.1.1.3. Regulatory Push for Enhanced Patient Enrollment Efficiency
      • 3.1.1.4. Rising Investments in Digital Health & Clinical Research Technologies
      • 3.1.1.5. Expanding Clinical Trial Pipelines & Decentralized Trials
      • 3.1.1.6. Partnerships Between Pharma Companies & Tech Firms for Advanced Solutions
    • 3.1.2. Market Restraint Analysis
      • 3.1.2.1. High Implementation and Maintenance Costs
      • 3.1.2.2. Data Privacy and Security Concerns
    • 3.1.3. Market Opportunities Analysis
  • 3.2. Clinical Trials Matching Software Market Analysis Tools
    • 3.2.1. Industry Analysis - Porter's
      • 3.2.1.1. Supplier power
      • 3.2.1.2. Buyer power
      • 3.2.1.3. Substitution threat
      • 3.2.1.4. Threat of new entrant
      • 3.2.1.5. Competitive rivalry
    • 3.2.2. PESTEL Analysis
      • 3.2.2.1. Political landscape
      • 3.2.2.2. Economic landscape
      • 3.2.2.3. Social landscape
      • 3.2.2.4. Technological landscape
      • 3.2.2.5. Environmental landscape
      • 3.2.2.6. Legal landscape
    • 3.2.3. Emerging Technologies
    • 3.2.4. Case Studies & Insights
    • 3.2.5. COVID-19 Impact Analysis

Chapter 4. Clinical Trials Matching Software Market: Deployment Mode Estimates & Trend Analysis

  • 4.1. Deployment Mode Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Clinical Trials Matching Software Market by Deployment Mode Outlook
  • 4.4. Web & Cloud-based
    • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5. On-Premises
    • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Clinical Trials Matching Software Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Clinical Trials Matching Software Market by End Use Outlook
  • 5.4. Pharmaceutical & Biotechnology Companies
    • 5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 5.5. CROs
    • 5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 5.6. Medical Device Companies
    • 5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Clinical Trials Matching Software Market: Regional Estimates & Trend Analysis, By Deployment Mode and By End Use

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. Mexico
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Norway
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.8. Denmark
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. Singapore market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.2. Argentina
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework
      • 6.9.1.3. Competitive scenario
      • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Key company market share/position analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. IBM
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Technology Type benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Antidote Technologies, Inc.
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Technology Type benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. RealTime Software Solutions, LLC
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Technology Type benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Optimapharm.
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Technology Type benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Advarra
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Technology Type benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. BSI Business Systems Integration AG
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Technology Type benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Clario
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Technology Type benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. HealthMatch
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Technology Type benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Microsoft
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Technology Type benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Deep6.ai
      • 7.4.10.1. Company overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Technology Type benchmarking
      • 7.4.10.4. Strategic initiatives
    • 7.4.11. Inspirata, Inc.
      • 7.4.11.1. Company overview
      • 7.4.11.2. Financial performance
      • 7.4.11.3. Technology Type benchmarking
      • 7.4.11.4. Strategic initiatives
    • 7.4.12. Mendel Health Inc.
      • 7.4.12.1. Company overview
      • 7.4.12.2. Financial performance
      • 7.4.12.3. Technology Type benchmarking
      • 7.4.12.4. Strategic initiatives
    • 7.4.13. MatchTrial
      • 7.4.13.1. Company overview
      • 7.4.13.2. Financial performance
      • 7.4.13.3. Technology Type benchmarking
      • 7.4.13.4. Strategic initiatives
    • 7.4.14. Curewiki
      • 7.4.14.1. Company overview
      • 7.4.14.2. Financial performance
      • 7.4.14.3. Technology Type benchmarking
      • 7.4.14.4. Strategic initiatives
    • 7.4.15. Inteliquet (IQVIA)
      • 7.4.15.1. Company overview
      • 7.4.15.2. Financial performance
      • 7.4.15.3. Technology Type benchmarking
      • 7.4.15.4. Strategic initiatives
    • 7.4.16. Tempus Labs
      • 7.4.16.1. Company overview
      • 7.4.16.2. Financial performance
      • 7.4.16.3. Technology Type benchmarking
      • 7.4.16.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 North America clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
  • Table 4 North America clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 5 U.S. clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
  • Table 6 U.S. clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 7 Canada clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
  • Table 8 Canada clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 9 Mexico clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
  • Table 10 Mexico clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 11 Europe clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
  • Table 12 Europe clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 13 UK clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
  • Table 14 UK clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 15 Germany clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
  • Table 16 Germany clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 17 France clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
  • Table 18 France clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 19 Italy clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
  • Table 20 Italy clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 21 Spain clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
  • Table 22 Spain clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 23 Sweden clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
  • Table 24 Sweden clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 25 Denmark clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
  • Table 26 Denmark clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 27 Norway clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
  • Table 28 Norway clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 31 Japan clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
  • Table 32 Japan clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 33 China clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
  • Table 34 China clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 35 India clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
  • Table 36 India clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 37 Australia clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
  • Table 38 Australia clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 39 South Korea clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
  • Table 40 South Korea clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 41 Thailand clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
  • Table 42 Thailand clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 43 Latin America clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
  • Table 44 Latin America clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 45 Brazil clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
  • Table 46 Brazil clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 47 Argentina clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
  • Table 48 Argentina clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 49 MEA clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
  • Table 50 MEA clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 51 South Africa clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
  • Table 52 South Africa clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 53 Saudi Arabia clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
  • Table 54 Saudi Arabia clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 55 UAE clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
  • Table 56 UAE clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 57 Kuwait clinical trials matching software market estimates and forecasts, by deployment mode, 2018 - 2030 (USD Million)
  • Table 58 Kuwait clinical trials matching software market estimates and forecasts, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Clinical Trials Matching Software Market Segmentation
  • Fig. 2 Information Procurement
  • Fig. 3 Data Analysis Models
  • Fig. 4 Market Formulation and Validation
  • Fig. 5 Data Validating & Publishing
  • Fig. 6 Market Snapshot
  • Fig. 7 Segment Snapshot (1/2)
  • Fig. 8 Segment Snapshot (2/2)
  • Fig. 9 Competitive Landscape Snapshot
  • Fig. 10 Clinical Trials Matching Software- Market Size and Growth Prospects (USD Million)
  • Fig. 11 Clinical Trials Matching Software Market: Industry Value Chain Analysis
  • Fig. 12 Clinical Trials Matching Software Market: Market Dynamics
  • Fig. 13 Clinical Trials Matching Software Market: PORTER's Analysis
  • Fig. 14 Clinical Trials Matching Software Market: PESTEL Analysis
  • Fig. 15 Clinical Trials Matching Software Market: Deployment Mode Movement Analysis, 2018 - 2030 (USD Million)
  • Fig. 16 Clinical Trials Matching Software Market Share Analysis by Deployment Mode, 2024 & 2030
  • Fig. 17 Web & Cloud-based Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 18 On-premises Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 19 Clinical Trials Matching Software Market: End Use Movement Analysis, 2018 - 2030 (USD Million)
  • Fig. 20 Clinical Trials Matching Software Market Share Analysis by End Use, 2024 & 2030
  • Fig. 21 Pharmaceutical & Biotechnology Companies Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 22 CROs Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 23 Medical Device Companiess Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 24 Clinical Trials Matching Software Market Revenue, by Region, 2024 & 2030 (USD Million)
  • Fig. 25 Regional Marketplace: Key Takeaways
  • Fig. 26 North America Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Canada Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Mexico Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Europe Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 UK Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030) (USD Million)
  • Fig. 32 Germany Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 France Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Italy Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Spain Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Sweden Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Denmark Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Norway Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Asia Pacific Clinical Trials Matching Software Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Japan Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 China Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 India Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Australia Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Thailand Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Latin America Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Brazil Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Argentina Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 MEA Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Saudi Arabia Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 UAE Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 South Africa Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Kuwait Clinical Trials Matching Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Key Company Categorization
  • Fig. 54 Company Market Positioning
  • Fig. 55 Key Company Market Share Analysis, 2024
  • Fig. 56 Strategic Framework